Basilsea reports positive data from ceftobiprole trials
Switzerland-based Basilea Pharmaceutica says that its broad-spectrum antibiotic ceftobiprole, which it is developing in partnership with Johnson & Johnson, has potent activity against methicillin-resistant Staphylococcus aureus. The announcement was made at the 45th annual Interscience Conference on Antimicrobial Agents and Chemotherapy, held in Washington DC, USA.
The data is derived from several studies of the compound which assessed its efficacy against MRSA and other hospital-acquired infections.
"With ceftobiprole progressing well in late-stage development for the treatment of severe bacterial infections and our water-soluble azole entering Phase III, we show our continued commitment and ability to develop anti-infective drugs with strong competitive profiles," commented Rienk Pypstra, the firm's chief development officer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze